Evidence map›Paper›PMID 33343293›Full record

ReviewFrontiers in neuroscience2020

Repositioning of Immunomodulators: A Ray of Hope for Alzheimer's Disease?

Antonio Munafò, Chiara Burgaletto, Giulia Di Benedetto, Marco Di Mauro, Rosaria Di Mauro, Renato Bernardini, Giuseppina Cantarella

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Antonio MunafòDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Chiara BurgalettoDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Giulia Di BenedettoDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Marco Di MauroDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Rosaria Di MauroDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Renato BernardiniDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Giuseppina CantarellaDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
University of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder characterized by cognitive decline and by the presence of amyloid β plaques and neurofibrillary tangles in the brain. Despite recent advances in understanding its pathophysiological mechanisms, to date, there are no disease-modifying therapeutic options, to slow or halt the evolution of neurodegenerative processes in AD. Current pharmacological treatments only transiently mitigate the severity of symptoms, with modest or null overall improvement. Emerging evidence supports the concept that AD is affected by the impaired ability of the immune system to restrain the brain's pathology. Deep understanding of the relationship between the nervous and the immune system may provide a novel arena to develop effective and safe drugs for AD treatment. Considering the crucial role of inflammatory/immune pathways in AD, here we discuss the current status of the immuno-oncological, immunomodulatory and anti-TNF-α drugs which are being used in preclinical studies or in ongoing clinical trials by means of the drug-repositioning approach.

Indexed as

clinical trialdisease-modifying therapydrug repurposingimmune responseneuroinflammation

Identifiers

PMID33343293
PMCPMC7746859
OpenAlexW3111897679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.